BioCryst Reports Third Quarter 2016 Financial Results

Go back to BioCryst Reports Third Quarter 2016 Financial Results

BioCryst Pharma (BCRX) Tops Q3 EPS by 8c

November 7, 2016 6:49 AM EST

BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.16), $0.08 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.94 million.

Cash, cash equivalents and investments decreased to $68.7 million at September 30, 2016, as compared to $100.9 million at... More